This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Hayashi, M. Articles by Sugihara, K. Search for Related Content PubMed PubMed Citation Articles by Hayashi, M. Articles by Sugihara, K.

High Expression of HER3 Is Associated with a Decreased Survival in Gastric Cancer

Authors' Affiliations: Departments of ¹ Surgical Oncology, ² Translational Oncology, ³ Esophagogastric Surgery, and ⁴ Human Pathology, Tokyo Medical and Dental University, Tokyo, Japan

Requests for reprints: Mikito Inokuchi, Department of Surgical Oncology, Tokyo Medical and Dental University, 1-5-45, Yushima, Bunkyo, Tokyo 113-8519, Japan. Phone: 813-5803-5261; Fax: 813-5803-0139; E-mail: m-inokuchi.srg2{at}tmd.ac.jp.

Background: The role of human epidermal growth factor receptor (HER) 3 and HER4 has been elucidated in gastric cancer. HER1 and HER2 overexpression are regarded as prognostic factors and targets of treatment. The dimerization of the HER family receptors activates downstream signal pathways and promotes tumor progression. This study investigated the positive correlation between HER1 and HER4 expression and the prognosis of patients with gastric cancers.

Experimental Design: Tumor samples were obtained from gastric adenocarcinomas of 134 patients who underwent a gastrectomy from 1999 to 2002. The expression of each HER was analyzed in the tumor by immunohistochemical staining. Parametric correlations were done between HER expression and the clinicopathologic findings. A multivariate analysis was done with the overall survival.

Results: HER3 expression was significantly associated with parameters involved with tumor progression, including the depth of tumor invasion (T₁ versus T₂-T₄; P = 0.000), involved lymph nodes (P = 0.000), distant metastasis (P = 0.008), tumor stage (P = 0.000), and recurrent disease (P = 0.000). HER1 was also significantly associated with those factors excluding distant metastasis. A significant relationship was observed between the expression of HER1 and HER3 (P = 0.000). HER3 overexpression was associated with a significantly worse survival (P = 0.0000) and was an independent prognostic factor in the multivariate analysis (hazard ratio, 2.382; 95% confidence interval, 1.009-5.625; P = 0.048).

Conclusions: HER3 overexpression is strongly associated with tumor progression and poor prognosis of patients with gastric cancer. It may become a new prognostic factor and a target of treatment.